Want to cut your energy bills? Here’s how five experts are doing it 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
ROCKVILLE, Md., March 09, 2016 -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the 28th Annual ROTH Conference on Tuesday, March 15, 2016 at 7:00 AM PT or 10:00 AM ET.
Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator.
The presentation will be webcast live and may be accessed from the Event Calendar page of Sucampo's website at http://www.sucampo.com/investors/events-presentations/. A replay of the webcast will also be available on the Company's website for several days after the live event. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. Sucampo has one marketed product – AMITIZA – and a pipeline of product candidates in clinical development. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the U.K. For more information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals).
Contact: Sucampo Pharmaceuticals, Inc. Silvia Taylor Senior Vice President, Investor Relations and Corporate Affairs 1-240-223-3718 [email protected]
